Current Report Filing (8-k)
September 21 2016 - 12:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): September 15, 2016
OPIANT PHARMACEUTICALS, INC.
(
Exact name
of registrant as specified in its charter)
Nevada
|
|
000-55330
|
|
46-4744124
|
(State or other jurisdiction
of
incorporation)
|
|
(Commission File Number
|
|
(IRS Employer
Identification No.)
|
401 Wilshire Blvd., 12th Floor
Santa Monica, CA
|
|
90401
|
(Address of Principal Executive
Offices)
|
|
(Zip Cope)
|
(424)
252-4756
Registrant’s telephone number, including
area code
|
(Former name or former address if changed since last report,)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On September 15, 2016, Opiant Pharmaceuticals, Inc. (the “Company”)
and ADAPT Pharma, Inc. (“ADAPT”) received notice from TEVA Pharmaceuticals USA, Inc. (“TEVA”), pursuant
to 21 U.S.C. § 355(j)(2)(B)(ii) (the “Notice Letter”), that TEVA had filed an Abbreviated New Drug Application
(“ANDA”) with the United States Food and Drug Administration (“FDA”) seeking regulatory approval to market
a generic version of NARCAN® (naloxone hydrochloride) Nasal Spray before the expiration of U.S. Patent No. 9,211,253 (the “’253
patent”). The ‘253 patent is listed with respect to NARCAN® in the FDA’s Approved Drug Products with Therapeutic
Equivalents Evaluation publication (commonly referred to as the “Orange Book”) and expires on March 16, 2035. TEVA’s
Notice Letter asserts that its generic product will not infringe the ‘253 patent or that the ‘253 patent is invalid
or unenforceable. The Company and ADAPT are evaluating TEVA’s Notice Letter.
The Company has full confidence in its intellectual property
portfolio related to NARCAN® and expects that the ‘253 patent will be vigorously defended from any infringement. The
Company may receive additional Notice Letters from other companies seeking to market generic versions of NARCAN® in the future
and, after evaluation, the Company may commence patent infringement lawsuits against such companies.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
Opiant Pharmaceuticals, Inc.
|
|
|
|
Date: September 21, 2016
|
By:
|
/s/
Dr. Roger Crystal
|
|
|
Name: Dr. Roger Crystal
|
|
|
Title: President and Chief Executive Officer
|
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Sep 2023 to Sep 2024